Health Care · Pharmaceutical Preparations

BCAX Bicara Therapeutics Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 202365885 filings
Russell 2000

BCAX at a glance

Bicara Therapeutics Inc. (BCAX, SEC CIK 2023658) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as September 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Bicara Therapeutics Inc. (BCAX) shares worth $329.5 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Cohlhepp Ryan on September 8, 2026 of 14,058 shares at $22.77 per share.
  • In the last 90 days, BCAX insiders reported 0 open-market purchases ($0) and 2 open-market sales ($401K) on Form 4, a net sale of $401K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 2 sells
Net −$401K
13F holders
25 funds
$329.5M · −3 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No explicit new risk factor identified versus the 10-K; filing presents existing risks without a change statement
  • Financial: $442.3 million cash, equivalents and marketable securities projected to fund operations into first half of 2029
  • Regulatory: BIOSECURE Act restrictions could impair supply from Chinese biotechnology partners, with prohibitions expected in 2027 at earliest
  • Operational: Reliance on WuXi Biologics for ongoing clinical supply creates concentration risk amid China-U.S. geopolitical tensions
  • Clinical: Ficerafusp alfa’s Phase 2/3 FORTIFI-HN01 trial faces enrollment, safety and regulatory approval uncertainty

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales or other revenue generated
  • Net loss $71.2M vs $36.3M YoY, operating expenses $75.7M vs $40.7M
  • R&D highest spending area: $56.5M vs $33.0M, driven by FORTIFI-HN01 and FORTIFI-FLEX
  • Cash, equivalents and marketable securities $442.3M; operating cash use $137.8M vs $82.9M
  • February offering added $161.8M; funding expected into first half of 2029, additional capital needed thereafter

AI summary of the BCAX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Bicara Therapeutics’ financial results for the quarter ended September 30, 2026
  • Business updates accompany the quarterly results, with substantive details in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • FORTIFI-HN01 achieved substantial enrollment, supporting topline interim results in mid-2027 for first-line HPV-negative HNSCC
  • Cash, equivalents and marketable securities reached $442.3 million, funding operations into the first half of 2029 under current plans
Filed Aug 25, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • New 35,090-square-foot Boston headquarters at 10 St. James Avenue
  • Base rent $105,279 monthly, payable nine months after commencement
Filed Aug 11, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Leadership succession: Ryan Cohlhepp becomes CEO January 1, 2027, while Claire Mazumdar transitions to Vice Chair and Strategic Advisor
  • FORTIFI-HN01 pivotal trial expected substantially enrolled by year-end, targeting interim topline results in mid-2027

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results and business updates announced for quarter ended June 30, 2026
  • Full results and operational details available in Exhibit 99.1 press release

AI summaries of BCAX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BCAX

Don't miss the next BCAX filing

  • Alerts as it files. A push when BCAX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BCAX, by share count.
  • Ask anything. An AI agent that reads every BCAX filing and answers with sources.

BCAX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Cohlhepp RyanMSep 8, 2026$3.79
Cohlhepp RyanSellSep 8, 2026$22.77
Cohlhepp RyanSellSep 8, 2026$23.43
Cohlhepp RyanMSep 8, 2026-
Larson JenniferAAug 12, 2026-
Hyep IvanSellAug 10, 2026$27.97
Hyep IvanMAug 10, 2026$3.79
Hyep IvanMAug 10, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$39.9M-$82.4M-$155.6M
Net Income--$68.0M-$137.9M
Balance Sheet
Total Assets$234.0M$510.0M$431.0M
Equity-$148.8M$491.9M$401.5M
ROE--13.8%-34.4%
Per Share
EPS$-89.61$-4.05$-2.52
Cash Flow
Operating CF-$45.6M-$74.8M-$106.8M
CapEx$586K$71K$280K

Source: XBRL data in Bicara Therapeutics Inc. (BCAX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BCAX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BCAX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$329.5M
Q2 202628$561.5M
Q1 202627$311.3M
Q4 202522$240.0M
Q3 202521$208.5M
Q2 202521$120.3M
Q1 202518$100.6M
Q4 202410$87.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 172 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BCAX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
4Sep 10, 2026--
8-KAug 25, 2026Analysis-
4Aug 14, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
10-QAug 11, 2026Analysis
8-KAug 11, 2026Analysis-
4Jul 29, 2026--
4Jul 29, 2026--
8-KJul 28, 2026Analysis-
SC 13GJul 27, 2026-
4Jul 14, 2026--
4Jul 10, 2026--
4Jul 10, 2026--
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
8-KJun 10, 2026Analysis
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-

Related Health Care companies

All Health Care →

BCAX SEC filings: frequently asked questions

Are BCAX insiders buying or selling?

In the last 90 days, Bicara Therapeutics Inc. (BCAX) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $400,716 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold BCAX stock?

As of September 30, 2026, the largest Bicara Therapeutics Inc. (BCAX) holders among the 13F filers tracked by SignalX were BlackRock ($73.4 million), Vanguard Capital Management LLC ($41.2 million), State Street Corp ($38.3 million), T. Rowe Price Group ($35.7 million), Franklin Resources ($23.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did BCAX report in its latest 8-K?

Bicara Therapeutics Inc. (BCAX) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Bicara Therapeutics’ financial results for the quarter ended September 30, 2026.

What are the latest BCAX SEC filings?

Bicara Therapeutics Inc. (BCAX) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on September 10, 2026.

What is BCAX's SEC CIK number?

Bicara Therapeutics Inc. (BCAX)'s SEC Central Index Key (CIK) is 2023658. EDGAR lists every BCAX filing under that number.

Ask anything about BCAX

The research agent reads BCAX's filings, financials, insider trades and 13F holders, then answers with sources.